CA Stock MarketDetailed Quotes
FRX Fennec Pharmaceuticals Inc
- 9.090
- +0.690+8.21%
15min DelayTrading Nov 27 12:34 ET
249.36MMarket Cap-168333P/E (TTM)
9.090High8.900Low2.23KVolume8.990Open8.400Pre Close20.06KTurnover15.43052wk High0.01%Turnover Ratio27.43MShares5.65052wk Low-0.054EPS TTM170.97MFloat Cap391.500Historical HighLossP/E (Static)18.81MShs Float0.270Historical Low-0.795EPS LYR2.26%Amplitude--Dividend TTM-34.17P/B1Lot Size--Div YieldTTM
About Fennec Pharmaceuticals Inc Company
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
Company Profile
SymbolFRX
Company NameFennec Pharmaceuticals Inc
Founded1998
MarketTSE
Employees29
Fiscal Year Ends12-31
Address68 TW Alexander Drive PO Box 13628
CityResearch Triangle Park
CountryUnited States of America
Zip Code27709
Phone+1 919 636-4530
Websitehttps://www.fennecpharma.com
Company Executives
- Name
- Position
- Salary
- Jeffrey S. Hackman
- Chief Executive Officer and Director
- --
- Christiana Cioffi, M.B.A.
- Chief Strategy Officer
- --
- Pierre S. Sayad, M.S.
- Chief Medical Officer
- --
- Terry Evans
- Chief Commercial Officer
- --
- Robert Andrade
- Chief Financial Officer and Principal Accounting Officer
- 1.31M
- Dr. Khalid Islam, PhD
- Chairman of the Board
- 225.23K
- Rostislav Raykov
- Director
- 2.54M
- Chris A. Rallis
- Independent Director
- 173.18K
- Dr. Marco M. Brughera
- Independent Director
- 166.31K
- Dr. Jodi A. Cook, PhD
- Independent Director
- 153.81K
Heat List
CA
Overall
Symbol
Latest Price
% Chg
No Data